You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
My Gene Counsel's confirmatory testing program is the latest example of how the healthcare system is adapting to consumers' growing appetite for genetic testing.
23andMe is now offering a type 2 diabetes risk test, according to MIT's Technology Review.
Healthcare providers continue to worry about the impact of 23andMe's health risk reports but there is also growing acceptance of the DTC testing model.
At-home genetic tests can uncover family secrets and lead those who uncover them to seek out support groups, the Boston Globe reports.
The revelation that Family Tree DNA has been working with law enforcement has some worried about a negative impact on the industry.
The New York Times warns in an editorial that 23andMe health risk tests may not provide useful information.
Using UK Biobank and 23andMe data, researchers found 352 loci influencing sleep time preferences, including sites near brain- and retina-expressed genes.
Direct-to-consumer genetic testing firm 23andMe has a newly cleared colorectal cancer risk test.
The clearance enables 23andMe to report on the two most common variations in the MUTYH gene influencing MAP, which increases risk of CRC development.
Identical twins receive different estimates of ancestry from the same direct-to-consumer genetic testing firms, CBC reports.
Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.
NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.
Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.
In Science this week: review discusses advances in liquid biopsies, and more.